VACCENTIS AG is a Zurich-based investment company focused on the biotech and pharmaceutical sector. The entire research, production and sales activities are carried out by two highly specialized  subsidiaries,  VCC  MEDICAL  and  FBM-  Pharma, which focus on special methods of personalized medicine

Products, services, technology

VCC-001 is an autologous tumour lysate vaccine
based on the individual patient’s tumour cells. Used in Renal
Cell Cancer (post-nephrectomy), VCC-001 shows:
– a highly specific immune response with evidence of excellent efficacy
– a very favourable safety and side effects profile

Some insights
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business